Journal of Endocrinological Investigation

, Volume 30, Issue 11, pp 944–947 | Cite as

Induction of vascular endothelial growth factor release by transcutaneous frequency modulated neural stimulation in diabetic polyneuropathy

  • M. Bevilacqua
  • L. J. Dominguez
  • M. Barrella
  • M. Barbagallo
Original Articles


Background: Pharmacological treatment for diabetic polyneuropathy (DP) has shown limited benefit; frequency-modulated electrical stimulation (FREMS) has shown positive results in pain control and nerve conduction velocity in DP. Objective: To investigate the effects of FREMS vs transcutaneous electrical nerve stimulation (TENS) on the release of vascular endothelial growth factor (VEGF) in Type 2 diabetic and in non-diabetic subjects. Methods: 10 non-diabetic [mean age 37±5 yr; females (F)/males (M): 6/4] and 10 Type 2 diabetic subjects (mean age 52±6 yr; F/M: 5/5) with DP underwent TENS (for 10 min) followed by 30 min interval without electrical stimulation, and then FREMS (for 10 min) over the forearm volar surface. Blood samples for VEGF measurements were obtained from the contra-lateral arm every 2 min during TENS/FREMS application and every 10 min during the intervals. Results: We observed a significant rise in plasma VEGF during FREMS in both non-diabetic and diabetic subjects (maximal response 89.4±80.3 pg/ml and 48.5±18.3 pg/ml, respectively; p<0.01 vs basal) with a lower, but still significant response in diabetics. No changes in VEGF were observed during TENS application. Conclusion: VEGF release during FREMS may help explain the positive effects on nerve conduction velocity in DP, possibly mediated by favorable effects on vasa nervorum microangiopathy.


Diabetic neuropathy diabetes mellitus VEGF electrical stimulation TENS 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Duby JJ, Campbell RK, Setter SM, White JR, Rasmussen KA. Diabetic neuropathy: an intensive review. Am J Health Syst Pharm 2004, 61: 160–73.PubMedGoogle Scholar
  2. 2.
    Tesfaye S, Chaturvedi N, Eaton SEM, et al; EURODIAB Prospective Complications Study Group. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005, 352: 341–50.PubMedCrossRefGoogle Scholar
  3. 3.
    Struijs JN, Baan CA, Schellevis FG, Westert GP, van den Bos GA. Comorbidity in patients with diabetes mellitus: impact on medical health care utilization. BMC Health Serv Res 2006, 6: 84.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Lavery LA, Wunderlich RP, Tredwell JL. Disease management for the diabetic foot: effectiveness of a diabetic foot prevention program to reduce amputations and hospitalizations. Diabetes Res Clin Pract 2005, 70: 31–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Cameron NE, Cotter MA. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes 1997, 46(Suppl 2): S31–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Veves A, King GL. Can VEGF reverse diabetic neuropathy in human subjects? J Clin Invest 2001, 107: 1215–8.PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Greene DA, Lattimer SA, Sima AA. Are disturbances of sorbitol, phosphoinositide, and Na+-K+-ATPase regulation involved in pathogenesis of diabetic neuropathy? Diabetes 1988, 37: 688–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Horrobin DF. Essential fatty acids in the management of impaired nerve function in diabetes. Diabetes 1997, 46(Suppl 2): S90–3.PubMedCrossRefGoogle Scholar
  9. 9.
    Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992, 15: 1835–43.PubMedCrossRefGoogle Scholar
  10. 10.
    Obrosova IG. How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 2002, 50: 3–35.PubMedCrossRefGoogle Scholar
  11. 11.
    Apfel SC, Arezzo JC, Brownlee M, Federoff H, Kessler JA. Nerve growth factor administration protects against experimental diabetic sensory neuropathy. Brain Res 1994, 634: 7–12.PubMedCrossRefGoogle Scholar
  12. 12.
    Granberg V, Ejskjaer N, Peakman M, Sundkvist G. Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005, 28: 1959–64.PubMedCrossRefGoogle Scholar
  13. 13.
    Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359: 843–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Kanno S, Oda N, Abe M, et al. Establishment of a simple and practical procedure applicable to therapeutic angiogenesis. Circulation 1999, 99: 2682–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electrostimulation. Diabetes Care 1997, 20: 1702–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Bosi E, Conti M, Vermigli C, et al. Effectiveness of a novel frequency modulated electro-magnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005, 48: 817–23.PubMedCrossRefGoogle Scholar
  17. 17.
    Schratzberger P, Walter DH, Rittig K, et al. Reversal of experimental diabetic neuropathy by VEGF gene transfer. J Clin Invest 2001, 107: 1083–92.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Barrella M, Toscano R, Goldoni M, Bevilacqua. Frequency rhythmic electrical modulation system (FREMS) on H-reflex amplitudes in healthy subjects. Eura Medicophys 2007, 43: 37–47.PubMedGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2007

Authors and Affiliations

  • M. Bevilacqua
    • 1
  • L. J. Dominguez
    • 2
  • M. Barrella
    • 1
  • M. Barbagallo
    • 2
  1. 1.Endocrinology and Diabetes Unit and LORENZ Research Center, Department of MedicineLuigi Sacco Hospital (Vialba)-University of MilanMilan
  2. 2.Geriatric Unit, Department of Internal Medicine and GeriatricsUniversity of PalermoPalermoItaly

Personalised recommendations